These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36283631)

  • 21. Indomethacin co-amorphous drug-drug systems with improved solubility, supersaturation, dissolution rate and physical stability.
    Fael H; Demirel AL
    Int J Pharm; 2021 May; 600():120448. PubMed ID: 33675920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Formulation of co-amorphous systems from naproxen and naproxen sodium and in situ monitoring of physicochemical state changes during dissolution testing by Raman spectroscopy.
    Ueda H; Peter Bøtker J; Edinger M; Löbmann K; Grohganz H; Müllertz A; Rades T; Østergaard J
    Int J Pharm; 2020 Sep; 587():119662. PubMed ID: 32682958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploring the physical stability of three nimesulide-indomethacin co-amorphous systems from the perspective of molecular aggregates.
    Wang M; Liu S; Jia L; Zhang J; Du S; Gong J
    Eur J Pharm Sci; 2020 Apr; 147():105294. PubMed ID: 32147483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How can we improve the physical stability of co-amorphous system containing flutamide and bicalutamide? The case of ternary amorphous solid dispersions.
    Pacułt J; Rams-Baron M; Chmiel K; Jurkiewicz K; Antosik A; Szafraniec J; Kurek M; Jachowicz R; Paluch M
    Eur J Pharm Sci; 2021 Apr; 159():105697. PubMed ID: 33568330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Drug Dissolution Rate in Co-amorphous and Co-crystal Binary Drug Delivery Systems by Thermodynamic and Kinetic Methods.
    Hu C; Zhang F; Fan H
    AAPS PharmSciTech; 2021 Jan; 22(1):21. PubMed ID: 33389277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physicochemical investigations and stability studies of amorphous gliclazide.
    Jondhale S; Bhise S; Pore Y
    AAPS PharmSciTech; 2012 Jun; 13(2):448-59. PubMed ID: 22382730
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and molecular insights of drug-active metabolite based co-amorphous formulation: A case study of toltrazuril-ponazuril co-amorphous.
    Li B; Wang Y; Feng Y; Yuan D; Xu R; Jiang C; Xiao X; Lu S
    Int J Pharm; 2022 Mar; 615():121475. PubMed ID: 35041914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How can we improve the physical stability of co-amorphous system containing flutamide and bicalutamide? The case of ternary amorphous solid dispersions.
    Pacult J; Rams-Baron M; Chmiel K; Jurkiewicz K; Antosik A; Szafraniec J; Kurek M; Jachowicz R; Paluch M
    Eur J Pharm Sci; 2019 Aug; 136():104947. PubMed ID: 31170526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The influence of co-formers on the dissolution rates of co-amorphous sulfamerazine/excipient systems.
    Gniado K; Löbmann K; Rades T; Erxleben A
    Int J Pharm; 2016 May; 504(1-2):20-6. PubMed ID: 26992818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Co-amorphous systems for the delivery of poorly water-soluble drugs: recent advances and an update.
    Han J; Wei Y; Lu Y; Wang R; Zhang J; Gao Y; Qian S
    Expert Opin Drug Deliv; 2020 Oct; 17(10):1411-1435. PubMed ID: 32683996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative analysis of binary and ternary cyclodextrin complexes with econazole nitrate in solution and in solid state.
    Jug M; Mennini N; Kövér KE; Mura P
    J Pharm Biomed Anal; 2014 Mar; 91():81-91. PubMed ID: 24444785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
    Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of polymer addition on the amorphization, dissolution and physical stability of co-amorphous systems.
    Liu J; Grohganz H; Rades T
    Int J Pharm; 2020 Oct; 588():119768. PubMed ID: 32798592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Permeability of glibenclamide through a PAMPA membrane: The effect of co-amorphization.
    Ruponen M; Visti M; Ojarinta R; Laitinen R
    Eur J Pharm Biopharm; 2018 Aug; 129():247-256. PubMed ID: 29894814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dissolution properties of co-amorphous drug-amino acid formulations in buffer and biorelevant media.
    Heikkinen AT; DeClerck L; Löbmann K; Grohganz H; Rades T; Laitinen R
    Pharmazie; 2015 Jul; 70(7):452-7. PubMed ID: 26373205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. On the role of salt formation and structural similarity of co-formers in co-amorphous drug delivery systems.
    Wu W; Löbmann K; Rades T; Grohganz H
    Int J Pharm; 2018 Jan; 535(1-2):86-94. PubMed ID: 29102703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of the p
    Hu Y; Guo Y; Li B; Xu R; Fang X; Cao Y; Liu Z; Jiang C; Lu S
    ACS Omega; 2021 Feb; 6(4):3106-3119. PubMed ID: 33553927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of physicochemical properties of ternary systems of oxaprozin with randomly methylated-ß-cyclodextrin and l-arginine aimed to improve the drug solubility.
    Mennini N; Maestrelli F; Cirri M; Mura P
    J Pharm Biomed Anal; 2016 Sep; 129():350-358. PubMed ID: 27454086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Organic acids as co-formers for co-amorphous systems - Influence of variation in molar ratio on the physicochemical properties of the co-amorphous systems.
    Wu W; Ueda H; Löbmann K; Rades T; Grohganz H
    Eur J Pharm Biopharm; 2018 Oct; 131():25-32. PubMed ID: 30040997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transformations between Co-Amorphous and Co-Crystal Systems and Their Influence on the Formation and Physical Stability of Co-Amorphous Systems.
    Wu W; Wang Y; Löbmann K; Grohganz H; Rades T
    Mol Pharm; 2019 Mar; 16(3):1294-1304. PubMed ID: 30624075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.